Open AccessPlasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Author(s) -
Laura L. Meijer,
Ingrid Garajová,
Chiara Caparello,
Tessa Y.S. Le Large,
Adam E. Frampton,
Enrico Vasile,
Niccola Funel,
Geert Kazemier,
Elisa Giovannetti
Publication year - 2018
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/sla.0000000000003084
Subject(s) - folfirinox , medicine , oxaliplatin , irinotecan , oncology , gemcitabine , hazard ratio , pancreatic cancer , cohort , adenocarcinoma , colorectal cancer , cancer , confidence interval
The aim of the study was to identify plasma microRNA (miRNA) biomarkers for stratifying and monitoring patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) treated with FOLFIRINOX, and to investigate their functional roles.